FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 Görünümler· 09/21/23
OncLive® On Air
OncLive® On Air
0 Aboneler
0
İçinde

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Daha fazla göster

 0 Yorumlar sort   Göre sırala


Bir sonraki